We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+87.18%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.49B
AUM Growth
+$574M
Cap. Flow
-$341M
Cap. Flow %
-13.72%
Top 10 Hldgs %
64.37%
Holding
51
New
1
Increased
2
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
AKUS
Akouos Inc
AKUS
+$95.8M
2
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$9.02M
3
TRVI icon
Trevi Therapeutics
TRVI
+$5.28M

Top Sells

Rank Stock Value
1
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$295M
2
EPZM
Epizyme, Inc
EPZM
+$67.9M
3
MRSN
Mersana Therapeutics
MRSN
+$54.7M
4
ARDX icon
Ardelyx
ARDX
+$17.4M
5
SENS icon
Senseonics Holdings Inc
SENS
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 79.28%
2 Technology 16.03%
3 Consumer Discretionary 2.25%
4 Industrials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPT icon
1
Sprout Social
SPT
$530M
$244M 9.82%
9,046,080
– –
MRSN
2
DELISTED
Mersana Therapeutics
MRSN
$186M 7.49%
318,381
-160,165
-33% -$54.7M
OYST
3
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$171M 6.88%
5,925,287
– –
ADAP
4
DELISTED
Adaptimmune Therapeutics
ADAP
$171M 6.87%
17,082,611
– –
ALLK
5
DELISTED
Allakos
ALLK
$163M 6.55%
2,268,188
– –
CRSP icon
6
CRISPR Therapeutics
CRSP
$4.65B
$154M 6.18%
2,090,678
– –
NET icon
7
Cloudflare
NET
$94.2B
$146M 5.87%
4,059,376
– –
BDTX icon
8
Black Diamond Therapeutics
BDTX
$95.1M
$145M 5.85%
3,449,845
– –
ELVN icon
9
Enliven Therapeutics
ELVN
$3.75B
$111M 4.46%
1,004,293
– –
RYTM icon
10
Rhythm Pharmaceuticals
RYTM
$7.36B
$110M 4.4%
4,912,306
– –
AKUS
11
DELISTED
Akouos Inc
AKUS
$96.7M 3.89%
+4,298,488
New +$95.8M
ARDX icon
12
Ardelyx
ARDX
$1.24B
$94.3M 3.79%
13,633,582
-2,501,465
-16% -$17.4M
AUPH icon
13
Aurinia Pharmaceuticals
AUPH
$1.92B
$84.1M 3.38%
5,172,683
– –
MIRM icon
14
Mirum Pharmaceuticals
MIRM
$6.65B
$81.5M 3.28%
4,187,801
– –
CSPR
15
DELISTED
Casper Sleep Inc.
CSPR
$55.8M 2.25%
6,226,040
– –
TRIL
16
DELISTED
Trillium Therapeutics Inc.
TRIL
$46.4M 1.87%
5,736,363
– –
TRVI icon
17
Trevi Therapeutics
TRVI
$2.54B
$39.1M 1.57%
5,940,796
+1,499,436
+34% +$5.28M
LITS
18
Lite Strategy Inc
LITS
$32.8M
$35.2M 1.42%
426,654
– –
CBIO
19
Crescent Biopharma
CBIO
$586M
$34.2M 1.37%
90,890
– –
GRTX
20
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$31.2M 1.25%
4,362,986
– –
PHAS
21
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$30.6M 1.23%
6,643,704
– –
AFMD
22
DELISTED
Affimed
AFMD
$28.3M 1.14%
612,649
– –
OBSV
23
DELISTED
ObsEva SA Ordinary Shares
OBSV
$27M 1.09%
4,586,563
– –
LQDA icon
24
Liquidia Corp
LQDA
$7.58B
$20.9M 0.84%
2,486,062
– –
AVEO
25
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$20.4M 0.82%
3,952,958
+1,428,571
+57% +$9.02M
1
2 3

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q2 2020 Portfolio in Review

As of Q2 2020, NEA Management Company held 51 positions worth $2.49B, up 30% from $1.91B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

NEA Management Company withdrew a net $341M in Q2 2020, closing 5 positions and reducing 3 holdings. Its most notable exit was Ra Pharmaceuticals, Inc. Common Stock, an estimated $295M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 84% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, NEA Management Company opened a new position in Akouos Inc worth $96.7M.

  • NEA Management Company's largest Q2 2020 buy was Akouos Inc: 4,298,488 shares worth $96.7M.
  • NEA Management Company added most to AVEO Pharmaceuticals, Inc. in Q2 2020, an estimated $9.02M increase.
  • NEA Management Company's biggest Q2 2020 reduction was Mersana Therapeutics, cutting an estimated $54.7M.
  • NEA Management Company fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $295M.
  • NEA Management Company's ten largest holdings make up 64% of its $2.49B portfolio in Q2 2020.
  • NEA Management Company opened 1 new position and closed 5 in Q2 2020.
  • NEA Management Company's portfolio value rose 30% quarter-over-quarter to $2.49B.

Based on NEA Management Company's 13F filing for Q2 2020, filed 5 Aug 2020.